Fig. 9

The potential of the signature as an indicator of immunotherapy response in PCa patients. Distribution of PD-1 (A), PD-L1 (B), PD-L2 (C), CTLA4 (D), B7H3 (E), and B7H4 (F) expression in the high and low-risk groups. Kaplan–Meier survival curves for the four patient groups stratified by risk score and PD-1 (G), PD-L1 (H), PD-L2 (I), CTLA4 (J), B7H3 (K), and B7H4 (L) expression. M The response rate to immunotherapy in the TCGA cohort of PCa patients based on the TIDE algorithm